Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?

被引:24
作者
Luo, Laihui [1 ]
He, Yongzhu [1 ]
Zhu, Guoqing [1 ]
Xiao, Yongqiang [1 ]
Song, Shengjiang [1 ]
Ge, Xian [2 ]
Wang, Tao [3 ]
Xie, Jin [1 ]
Deng, Wei [1 ]
Hu, Zhigao [1 ]
Shan, Renfeng [1 ,4 ]
机构
[1] First Affiliated Hosp Nanchang, Dept Gen Surg, Nanchang, Peoples R China
[2] First Affiliated Hosp Nanchang, Dept Pathol, Nanchang, Peoples R China
[3] First Affiliated Hosp Nanchang, Dept Day Surg Ward, Nanchang, Peoples R China
[4] Nanchang Univ, Affiliated Hosp 1, Dept Gen Surg, 17 Yong Wai Zheng St, Nanchang 330006, Peoples R China
关键词
hepatocellular carcinoma; conversion therapy; hepatectomy; post-hepatectomy liver failure; pathological complete response; HEPATOCELLULAR-CARCINOMA; TRANSARTERIAL CHEMOEMBOLIZATION; CHEMOTHERAPY; OXALIPLATIN; MANAGEMENT; OUTCOMES;
D O I
10.2147/JHC.S388965
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Conversion therapy gives some patients with initially unresectable hepatocellular carcinoma (HCC) access to surgery. The purpose of this study was to evaluate the safety and efficacy of hepatectomy after conversion therapy and how it differed from those who undergoing direct hepatectomy.Patients and Methods: From January 2018 to April 2022, 745 patients underwent hepatectomy for HCC were enrolled. Among them, 41 patients of unresectable HCC underwent hepatectomy after conversion therapy. A demographically and clinically comparable cohort was created from the remaining patients in a 1:1 ratio using propensity score matching.Results: The median duration of conversion therapy was 108 (42-298) days, 8 patients achieved complete response (CR) and 33 achieved partial response (PR). Conversion therapy resulted in some degree of myelosuppression, but liver function index remained good. Compared with the direct hepatectomy group, the conversion group had more blood loss (600 mL vs 400 mL,p=0.015), longer operative time (270 min vs 240 min, p=0.02), higher blood transfusion rates, and longer hospital stay (8 days vs 11 days,p<0.001). Patients in the conversion group had significantly more complications of any grade (82.9% vs 51.2%, p=0.002) and grade 3/4 (26.8% vs 4.9%, p=0.013), and 6 patients developed post-hepatectomy liver failure (PHLF). There were no deaths in either group. All patients achieved R0 resection, 6 (6/41, 14.6%) achieved pathological complete response (pCR), 14 achieved major pathologic responses (MPR). During a median follow-up of 12.8 months, 14 patients in the conversion group experienced recurrence or metastasis, no deaths.Conclusion: Hepatectomy after conversion therapy was more difficult than direct hepatectomy, but accurate preoperative assessment could ensure the safety of the surgery. The damage of liver function after conversion therapy was more severe than expected, PHLF should be prevented and treated. Hepatectomy was effective and necessary, postoperative pathological examination could provide guidance for adjuvant therapy.
引用
收藏
页码:1353 / 1368
页数:16
相关论文
共 37 条
[11]   Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].
Finn, Richard S. ;
Qin, Shukui ;
Ikeda, Masafumi ;
Galle, Peter R. ;
Ducreux, Michel ;
Kim, Tae-You ;
Kudo, Masatoshi ;
Breder, Valeriy ;
Merle, Philippe ;
Kaseb, Ahmed O. ;
Li, Daneng ;
Verret, Wendy ;
Xu, Derek-Zhen ;
Hernandez, Sairy ;
Liu, Juan ;
Huang, Chen ;
Mulla, Sohail ;
Wang, Yulei ;
Lim, Ho Yeong ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905
[12]   Hepatocellular carcinoma [J].
Forner, Alejandro ;
Reig, Maria ;
Bruix, Jordi .
LANCET, 2018, 391 (10127) :1301-1314
[13]   Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma [J].
He, Min-Ke ;
Liang, Run-Bin ;
Zhao, Yang ;
Xu, Yu-Jie ;
Chen, Huan-Wei ;
Zhou, Yuan-Min ;
Lai, Zhi-Cheng ;
Xu, Li ;
Wei, Wei ;
Zhang, Yao-Jun ;
Chen, Min-Shan ;
Guo, Rong-Ping ;
Li, Qi-Jiong ;
Shi, Ming .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[14]   Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy [J].
Iacovelli, Roberto ;
Palazzo, Antonella ;
Procopio, Giuseppe ;
Santoni, Matteo ;
Trenta, Patrizia ;
De Benedetto, Angelina ;
Mezi, Silvia ;
Cortesi, Enrico .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) :929-938
[15]   Local and Regional Therapies for Hepatocellular Carcinoma [J].
Kloeckner, Roman ;
Robert Galle, Peter ;
Bruix, Jordi .
HEPATOLOGY, 2021, 73 :137-149
[16]   Salvage surgery following downstaging of unresectable hepatocellular carcinoma [J].
Lau, WY ;
Ho, SKW ;
Yu, SCH ;
Lai, ECH ;
Liew, CT ;
Leung, TWT .
ANNALS OF SURGERY, 2004, 240 (02) :299-305
[17]   Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review of Efficacy and Safety Data [J].
Lencioni, Riccardo ;
de Baere, Thierry ;
Soulen, Michael C. ;
Rilling, William S. ;
Geschwind, Jean-Francois H. .
HEPATOLOGY, 2016, 64 (01) :106-116
[18]   Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma [J].
Llovet, Josep M. ;
De Baere, Thierry ;
Kulik, Laura ;
Haber, Philipp K. ;
Greten, Tim F. ;
Meyer, Tim ;
Lencioni, Riccardo .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2021, 18 (05) :293-313
[19]   Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases [J].
Marrero, Jorge A. ;
Kulik, Laura M. ;
Sirlin, Claude B. ;
Zhu, Andrew X. ;
Finn, Richard S. ;
Abecassis, Michael M. ;
Roberts, Lewis R. ;
Heimbach, Julie K. .
HEPATOLOGY, 2018, 68 (02) :723-750
[20]   Liver regeneration: biological and pathological mechanisms and implications [J].
Michalopoulos, George K. ;
Bhushan, Bharat .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2021, 18 (01) :40-55